# Radboudumc account plan

> Radboudumc is the university medical centre of Nijmegen, one of eight Dutch UMCs: €1,619.8m 2025 revenue, 12,702 employees.

## At a glance

Radboudumc (Stichting Radboud universitair medisch centrum) is the university medical centre of Nijmegen and one of the eight Dutch university medical centres, providing mostly highly complex, top-referral patient care alongside medical education and research; Radboud University's medical faculty is part of it. In 2025 it treated 219,010 unique patients, with 485,464 outpatient consultations and 30,918 operations. Consolidated revenue was €1,619.8m in 2025 (2024: €1,534.6m) and the net result €32.8m, with an EBITDA margin of 7.90%. It had 12,702 employees, an average of 8,964 FTE. Funding comes mainly from health insurers, government availability payments and Ministry of Education grants.

## Business units

- **Patient care** (about 74.5% of 2025 revenue (€1,206.1m)): Top-referral academic care delivered in 11 centres, each led by a medical, business and nursing director, with hospital-wide policy set by the Institute for Patient Care. Revenue comes mainly from insurers under the Zorgverzekeringswet (€952.9m) plus availability payments, including for the helicopter service and trauma centre.
- **Education and training (Radboudumc Health Academy)** (about 12.1% of 2025 revenue (€196.3m OCW grants)): Academic programmes in medicine, dentistry and biomedical sciences, medical specialist training, nursing and allied-health training and continuing education, with 3,446 enrolled academic students in 2025. A new 2026-2030 education strategy was prepared against announced national cuts.
- **Research (Research Institute for Medical Innovation)** (about 9.2% of 2025 revenue (€148.5m third-party contract research)): One institute with 47 research programmes and about 170 research groups, led by director of research Guillén Fernández. It produced 3,838 publications and 277 PhD theses in 2025, and its 2018-2024 SEP evaluation rated it excellent; spin-offs include SPL Medical and Plain Medical.

## Strategic priorities

- **Dealing with scarcity**: For 2026 the main focus is scarcity of people and resources: reducing care demand, portfolio choices, shifting care to regional hospitals and appropriate care, plus capacity management and staff retention and recruitment.
- **Financial resilience**: The board decided to lift the EBITDA margin to at least 8% within three years and raised its internal solvency norm to 30% for 2026, expecting financial tightening rather than easing.
- **Leading role in AI and medical technology**: A Data & AI Table was installed in 2025 and a comprehensive Data & AI strategy across care, research and education is under development, aligned with the European Health Data Space.
- **Focused research portfolio**: Research programmes will be merged, dissolved or supported to maturity, and five will be designated top programmes for six years; action plans are due by October 2026.
- **Advanced therapies**: Radboudumc backs more pharmaceutical and advanced-therapy development, as most launched products so far are MedTech; a central cleanroom for advanced therapies is due end 2026.

## Investments and deals

- **Masterplan Bouw**: The building masterplan runs to 2030 and is being re-baselined to a 2050 horizon, with a new masterplan and business case expected end 2027; 2025 tangible capex was €95.3m.
- **Clinical infrastructure projects**: A new central sterilisation and scope disinfection unit (Q2 2026), patient-care laboratories in building F (mid-2026), renovation of the east-flank care buildings and planning for Radiotherapy building G.
- **Cleanroom for advanced therapies**: A central cleanroom for advanced therapies due end 2026, supporting the push into pharmaceutical and advanced-therapy development.
- **AI in the electronic health record**: An Augmented Response Technology pilot in Epic ran with 4 departments, with a second round planned for 5 more in 2026.

## Challenges and risks

- **Funding cuts**: The board expects cuts to education and research funding and substantial healthcare cuts to fund rising defence spending.
- **Staff shortages**: Radboudumc had 770 vacancies at the end of 2025 and absenteeism of 5.56%; sufficient qualified staff is a named strategic risk.
- **Cybersecurity and regulation**: Several intrusion attempts were recorded in 2025, none disruptive; preparation for the Cyberbeveiligingswet, NIS2 and the EU AI Act is underway.
- **Geopolitics and prices**: Geopolitical tension and trade barriers affecting prices are named risks; the crisis plan was updated, including the reception of military casualties.

## What leadership says

> "They are not corrective; they are invitations to keep improving. That is exactly the culture we want: not being satisfied with the status quo." — Guillén Fernández, Scientific Director, Research Institute for Medical Innovation, Interview on the SEP evaluation 2018-2024, Radboudumc website

> "This evaluation report is reassuring, but the real work starts now." — Guillén Fernández, Scientific Director, Research Institute for Medical Innovation, Interview on the SEP evaluation 2018-2024, Radboudumc website


## Where a supplier can help

- **Workforce and capacity tools**: With scarcity the main 2026 focus and 770 vacancies, capacity management, scheduling, recruitment and staff-retention offers tie directly to a stated priority.
- **Data, AI and Epic integration**: The Data & AI strategy, the Augmented Response Technology pilot in Epic and FAIR data work create room for clinical AI, data stewardship and integration partners.
- **Building and clinical equipment**: Masterplan Bouw renovations, the new sterilisation unit and the advanced-therapy cleanroom open opportunities for construction, equipment and cleanroom suppliers.
- **Cybersecurity compliance**: Preparation for NIS2 and the Cyberbeveiligingswet, after several intrusion attempts in 2025, points to security services and compliance tooling.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Jaarverslag 2025 (annual report and consolidated financial statements 2025)](https://www.radboudumc.nl/getmedia/3226404e-0f5c-4644-8cc8-077ef42ab5b7/Radboudumc-Jaarverslag-2025.pdf)

Annual report

- Radboudumc (Stichting Radboud universitair medisch centrum, Nijmegen) is one of the eight Dutch university medical centres: top-referral academic patient care, education and research, under the mission "to have a significant impact on health and healthcare".
- FY2025 consolidated revenue €1,619.8m (2024: €1,534.6m, +5.5%); operating costs €1,577.8m (+4.0%); net result €32.8m (2024: €10.2m); EBITDA margin 7.90% (2024: 6.99%).
- Revenue mix: patient care €1,206.1m (of which Zorgverzekeringswet €952.9m), government education & research grants €196.3m, other operating income €217.4m including third-party contract research €148.5m (+12.7%).
- Scale 2025: 219,010 unique patients, 22,939 admissions, 485,464 outpatient consultations, 30,918 operations; 12,702 employees, average 8,964 FTE; 3,838 scientific publications, 277 PhD theses, 11 patent applications.
- The Fit for the Future reorganisation was completed in 2025: 11 patient-care centres, 3 institutes (one per core task), 38 medical and 3 scientific departments plus staff services.
- Balance sheet: solvency 31.8% (internal norm 28%, raised to 30% for 2026); cash €171m plus a €90m overdraft facility; long-term bank debt €451m with BNG Bank, EIB, ABN AMRO and Rabobank. The board decided to lift the EBITDA margin to at least 8% within three years.
- Masterplan Bouw runs to 2030 and is being re-baselined to a 2050 horizon (new Masterplan and business case expected end 2027); 2025 tangible capex €95.3m. Projects include a central cleanroom for advanced therapies (end 2026) and a new sterilisation unit (Q2 2026).
- Board: Bertine Lahuis (chair), Jan Smit (vice-chair/dean), Lot Winkel (CFO, from 1 Feb 2025), Frédérique van Berkestijn (COO, from 1 Apr 2025). The board expects financial tightening rather than easing, citing pressure on income and expected cuts to education and research funding.

### [Executive Response to the SEP Evaluation 2018-2024 of the Radboudumc Research Institute for Medical Innovation](https://www.ru.nl/sites/default/files/2026-05/executive-response-to-the-radboudumc-sep-evaluation-2018-2024.pdf)

Report · 2026-05-07

- The Executive Response, dated 7 May 2026, answers the international SEP evaluation 2018-2024 of the Radboudumc Research Institute for Medical Innovation, which rated the institute excellent, high-performing and internationally competitive.
- The committee endorsed the recent reorganisation: one institute including business development, goal-directed research programmes, a new financial model, the Scientific Career Path and the Research Group Leader structure.
- Radboudumc will move from a rich landscape to a more focused portfolio: research programmes will be merged, dissolved or supported to maturity. The committee's benchmark is about 30 programmes, and Radboudumc will balance focus with feasibility.
- Five research programmes will be designated "top programs" for six years, with extra visibility and grant-writing and business-development support.
- "Strategic prioritization, rather than across-the-board cuts" will guide financial decisions, particularly for innovation, AI, unique research assets and the Radboudumc Technology Centers.
- Radboudumc backs more pharmaceutical and advanced-therapy development (most launched products so far are MedTech), using clean rooms and business-development integration.
- A comprehensive Data & AI strategy across care, research and education is under development, with FAIR data and alignment with the European Health Data Space.
- Supervisory training will become mandatory for all Research Group Leaders within five years. A long-term alumni survey and central support for patient and citizen panels are planned.

### [Interview with Guillén Fernández: SEP evaluation 2018-2024 of Radboudumc research](https://www.radboudumc.nl/en/research/ambition-and-impact/Interview-with-Guillen-Fernandez)

Executive talk · Guillén Fernández, Scientific Director (director of research), Radboudumc Research Institute for Medical Innovation

- Guillén Fernández is the Scientific Director (director of research) of Radboudumc's Research Institute for Medical Innovation (RIMI). He comments on the 2018-2024 SEP evaluation of the institute.
- The international committee rated Radboudumc's research "excellent, high-performing, and internationally competitive" and backed the merger of research, support and business development into one institute with a new funding model, research programmes and a scientific career path.
- Fernández: "we have built a new research organization together, by the way we are conducting, organizing, and financing research".
- He sees the committee's dozens of recommendations as "invitations to keep improving", not corrections.
- His main takeaway is focus: fewer research programmes per research group, fewer programmes overall and five selected top programmes. He hopes this "will help us digest the upcoming budget cuts while maintaining excellent research quality and significant impact".
- Context on the same page: more than 3,500 peer-reviewed articles a year, over €235 million in research funding a year, nearly one in five publications in the world's top 10% most cited, and 8 ERC Advanced Grants in the evaluation period.
- Action plans for the institute and its 47 research programmes were discussed on 17 June 2026 and are to be final by October 2026, with an internal midterm assessment in 2028 and the next SEP in 2031.

### [Bertine Lahuis, opening column 'Hoopvol', Radbode #5 (December 2025)](https://www.radboudumc.nl/getmedia/f7556cae-0999-4063-b54e-56b4468eddd4/Radboudumc_Radbode_5.pdf)

Executive talk · Bertine Lahuis, Chair of the Executive Board

- Bertine Lahuis, chair of the Radboudumc Executive Board, wrote the opening column of the December 2025 staff magazine Radbode (#5, theme "Hoopvol", hopeful). Quotes below are translated from Dutch.
- She points to geopolitical tension, climate change and social inequality, and welcomes the recent Dutch election result: "political stability is dawning on the horizon".
- She calls a well-functioning democracy the basis for fair allocation of resources "also in healthcare", needed to reduce health inequalities and keep care "accessible, available and affordable".
- She calls the Fit for the Future reorganisation "an intensive process" that left the organisation stronger. Centres now seek more collaboration, and Radboudumc is growing "from an organisation of professionals into a professional organisation of professionals".
- Radboudumc asks hard questions about appropriate care: which care truly adds to a person's quality of life?
- Closer cooperation with regional hospitals is framed as a portfolio question: what should a umc do, and can certain care be delivered better elsewhere? She calls these "exciting questions, but necessary for future-proof healthcare".
- She wishes staff "a healthy, vital, innovative and daring 2026".

## Questions about Radboudumc

### What does Radboudumc do?

Radboudumc is the university medical centre of Nijmegen, providing highly complex top-referral patient care, medical education and research, organised in 11 patient-care centres and three institutes.

### What is Radboudumc's revenue?

Consolidated revenue was €1,619.8m in 2025, up from €1,534.6m in 2024, with a net result of €32.8m.

### How many employees does Radboudumc have?

Radboudumc had 12,702 employees in 2025, an average of 8,964 FTE.

### Who leads Radboudumc?

The Executive Board is chaired by Bertine Lahuis, with Jan Smit as vice-chair and dean, Lot Winkel as CFO and Frédérique van Berkestijn as COO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
